Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $22.31 billion. The enterprise value is $30.32 billion.
Important Dates
The last earnings date was Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | Nov 14, 2025 |
Share Statistics
Royalty Pharma has 577.24 million shares outstanding. The number of shares has decreased by -3.98% in one year.
| Current Share Class | 427.25M |
| Shares Outstanding | 577.24M |
| Shares Change (YoY) | -3.98% |
| Shares Change (QoQ) | -0.48% |
| Owned by Insiders (%) | 11.75% |
| Owned by Institutions (%) | 78.89% |
| Float | 374.60M |
Valuation Ratios
The trailing PE ratio is 22.06 and the forward PE ratio is 7.72. Royalty Pharma's PEG ratio is 0.74.
| PE Ratio | 22.06 |
| Forward PE | 7.72 |
| PS Ratio | 7.14 |
| Forward PS | 6.79 |
| PB Ratio | 2.59 |
| P/TBV Ratio | 4.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 9.28 |
| PEG Ratio | 0.74 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 39.64 |
| EV / Sales | 12.90 |
| EV / EBITDA | n/a |
| EV / EBIT | 19.41 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.48, with a Debt / Equity ratio of 0.93.
| Current Ratio | 3.48 |
| Quick Ratio | 3.47 |
| Debt / Equity | 0.93 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 5.59 |
Financial Efficiency
Return on equity (ROE) is 13.11% and return on invested capital (ROIC) is 5.36%.
| Return on Equity (ROE) | 13.11% |
| Return on Assets (ROA) | 5.22% |
| Return on Invested Capital (ROIC) | 5.36% |
| Return on Capital Employed (ROCE) | 8.30% |
| Revenue Per Employee | $23.74M |
| Profits Per Employee | $7.73M |
| Employee Count | 99 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +49.81% in the last 52 weeks. The beta is 0.47, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +49.81% |
| 50-Day Moving Average | 36.96 |
| 200-Day Moving Average | 34.83 |
| Relative Strength Index (RSI) | 53.67 |
| Average Volume (20 Days) | 4,002,013 |
Short Selling Information
The latest short interest is 14.19 million, so 2.46% of the outstanding shares have been sold short.
| Short Interest | 14.19M |
| Short Previous Month | 13.58M |
| Short % of Shares Out | 2.46% |
| Short % of Float | 3.79% |
| Short Ratio (days to cover) | 5.93 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.35 billion and earned $764.96 million in profits. Earnings per share was $1.75.
| Revenue | 2.35B |
| Gross Profit | 2.50B |
| Operating Income | 1.56B |
| Pretax Income | 1.30B |
| Net Income | 764.96M |
| EBITDA | n/a |
| EBIT | 1.56B |
| Earnings Per Share (EPS) | $1.75 |
Full Income StatementBalance Sheet
The company has $955.04 million in cash and $8.97 billion in debt, giving a net cash position of -$8.01 billion or -$13.88 per share.
| Cash & Cash Equivalents | 955.04M |
| Total Debt | 8.97B |
| Net Cash | -8.01B |
| Net Cash Per Share | -$13.88 |
| Equity (Book Value) | 9.62B |
| Book Value Per Share | 14.95 |
| Working Capital | 1.32B |
Full Balance SheetMargins
Gross margin is 106.59%, with operating and profit margins of 66.48% and 32.55%.
| Gross Margin | 106.59% |
| Operating Margin | 66.48% |
| Pretax Margin | 55.43% |
| Profit Margin | 32.55% |
| EBITDA Margin | n/a |
| EBIT Margin | 66.48% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $0.88, which amounts to a dividend yield of 2.28%.
| Dividend Per Share | $0.88 |
| Dividend Yield | 2.28% |
| Dividend Growth (YoY) | 4.76% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 50.24% |
| Buyback Yield | 3.98% |
| Shareholder Yield | 6.26% |
| Earnings Yield | 3.43% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for Royalty Pharma is $46.00, which is 19.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.00 |
| Price Target Difference | 19.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 14.15% |
| EPS Growth Forecast (5Y) | 31.14% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.49 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.49 |
| Piotroski F-Score | 6 |
